Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Bruker Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Bruker yıllık ortalama 17.4% oranında kazançlarını artırırken, Life Sciences sektöründe kazançlar growing at 13.6% annual. Gelirler growing yılda ortalama 9.6% oranında artmaktadır. Bruker'in özkaynak karlılığı 19.3% ve net marjı 11.3%'dir.

Anahtar bilgiler

17.4%

Kazanç büyüme oranı

18.8%

EPS büyüme oranı

Life Sciences Sektör Büyümesi	21.5%
Gelir büyüme oranı	9.6%
Özkaynak getirisi	19.3%
Net Marj	11.3%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations

May 09

Recent updates

Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price

Jun 09

Bruker: A Confusing Acquisition Spree

May 31

Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations

May 09

Bruker Corporation: An Aggressive Acquisition Strategy

Apr 24

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Apr 11

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

Jan 22

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Jan 08

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Dec 26

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Nov 06

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Oct 23

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Sep 25

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Aug 09

Is Now The Time To Look At Buying Bruker Corporation (NASDAQ:BRKR)?

Jul 27

Bruker (NASDAQ:BRKR) Has A Pretty Healthy Balance Sheet

Jul 11

If EPS Growth Is Important To You, Bruker (NASDAQ:BRKR) Presents An Opportunity

Jun 26

Gelir ve Gider Dağılımı

Bruker nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

NasdaqGS:BRKR Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 24	3,120	352	804	329
31 Mar 24	3,001	402	762	308
31 Dec 23	2,965	427	730	295
30 Sep 23	2,818	319	687	275
30 Jun 23	2,715	319	644	260
31 Mar 23	2,621	312	625	248
31 Dec 22	2,531	297	608	236
30 Sep 22	2,506	275	598	231
30 Jun 22	2,476	274	605	226
31 Mar 22	2,458	282	577	223
31 Dec 21	2,418	277	563	221
30 Sep 21	2,362	270	544	220
30 Jun 21	2,264	238	518	216
31 Mar 21	2,118	204	485	204
31 Dec 20	1,988	158	472	198
30 Sep 20	1,960	158	470	188
30 Jun 20	1,970	165	480	185
31 Mar 20	2,035	177	503	190
31 Dec 19	2,073	197	500	188
30 Sep 19	2,026	207	491	186
30 Jun 19	1,972	189	473	182
31 Mar 19	1,925	184	459	177
31 Dec 18	1,896	180	449	173
30 Sep 18	1,873	98	443	172
30 Jun 18	1,842	92	440	171
31 Mar 18	1,813	84	432	167
31 Dec 17	1,766	79	420	162
30 Sep 17	1,706	151	407	157
30 Jun 17	1,664	161	399	154
31 Mar 17	1,621	152	396	151
31 Dec 16	1,611	154	394	148
30 Sep 16	1,619	146	393	148
30 Jun 16	1,621	111	393	144
31 Mar 16	1,646	119	390	145
31 Dec 15	1,624	102	392	146
30 Sep 15	1,654	66	408	151
30 Jun 15	1,677	60	420	158
31 Mar 15	1,739	55	436	165
31 Dec 14	1,809	57	451	174
30 Sep 14	1,853	66	451	182
30 Jun 14	1,872	77	449	185
31 Mar 14	1,870	83	441	187
31 Dec 13	1,839	80	438	191

Kaliteli Kazançlar: BRKR yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: BRKR 'nin mevcut net kar marjları (11.3%) geçen yılın (11.8%) değerinden daha düşüktür.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: BRKR şirketinin kazancı son 5 yılda yılda 17.4% oranında arttı.

Büyüme Hızlandırma: BRKR 'un son bir yıldaki kazanç büyümesi ( 10.3% ) 5 yıllık ortalamasının ( 17.4% /yıl) altındadır.

Kazançlar vs. Sektör: BRKR geçen yılki kazanç büyümesi ( 10.3% ) Life Sciences sektörünün -11.3% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: BRKR 'nin Özsermaye Getirisi ( 19.3% ) düşük olarak değerlendiriliyor.

Bruker Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 3/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Second quarter 2024 earnings: EPS misses analyst expectations

Bruker Corporation to Report Q2, 2024 Results on Aug 06, 2024

Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bruker Corporation to Report Q1, 2024 Results on May 02, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Recent updates

Bruker Corporation (NasdaqGS:BRKR) acquired Dynamic Biosensors GmbH.

We Think Bruker (NASDAQ:BRKR) Is Taking Some Risk With Its Debt

Bruker: Multiple Risks And Declining Returns On Capital Aren't Priced In

Second quarter dividend of US$0.05 announced

Bruker Corporation Announces Quarterly Cash Dividend, Payable on September 16, 2024

Second quarter 2024 earnings: EPS misses analyst expectations

Bruker Corporation to Report Q2, 2024 Results on Aug 06, 2024

Is It Too Late To Consider Buying Bruker Corporation (NASDAQ:BRKR)?

Bruker Corporation Announces Suspension of Injunction Impacting NanoString's CosMx Spatial Molecular Imager Products in Germany

Bruker Corporation Announces Successful Installation of a 1.2 GHz NMR at the Leibniz Forschungsinstitut Für Molekulare Pharmakologie (FMP) in Berlin

Bruker Corporation's (NASDAQ:BRKR) Business Is Yet to Catch Up With Its Share Price

Bruker Corporation Launches Ultimate Sensitivity timsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

Bruker: A Confusing Acquisition Spree

Investor sentiment deteriorates as stock falls 15%

New minor risk - Shareholder dilution

Bruker Corporation has completed a Follow-on Equity Offering.

First quarter dividend of US$0.05 announced

Bruker Corporation Announces Quarterly Dividend, Payable on June 17, 2024

Bruker's (NASDAQ:BRKR) Promising Earnings May Rest On Soft Foundations

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Substantially all assets from NanoString Technologies, Inc. (OTCPK:NSTG.Q), NanoString Technologies Germany GmbH, Nanostring Technologies International, Inc. and NanoString Technologies Netherlands B.V.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bruker Corporation Revises Earnings Guidance for the Year 2024

Now 23% undervalued after recent price drop

Bruker Corporation to Report Q1, 2024 Results on May 02, 2024

Bruker Further Enhances Clinical Microbiology & Infection Diagnostics Portfolio at ESCMID Global 2024 Conference

Bruker Corporation: An Aggressive Acquisition Strategy

Bruker Corporation, Annual General Meeting, May 30, 2024

Bruker Offers Upside With Key Enabling Technologies For Future Bio-Pharma Research

Bruker Advances Magnet Technology for Broader Adoption of NMR in Academic and Biopharma Research, and Process Analytical Technologies

Bruker Corporation Advances CCS-Enabled 4D-Proteomics timsTOF Solutions for Immunopeptidomes and Glycoproteomics at US HUPO

Bruker Corporation (NasdaqGS:BRKR) completed the acquisition of Chemspeed Technologies AG.

President of Bruker BioSpin Group notifies of intention to sell stock

Insider recently sold US$822k worth of stock

Tecfin S.À R.L. entered into an agreement to acquire Identicare Limited from Tecfin S.À R.L. for €870 million.

Insider notifies of intention to sell stock

Fourth quarter dividend of US$0.05 announced

Consensus EPS estimates increase by 25%

Bruker Corporation Approves Payment of A Quarterly Cash Dividend, Payable on March 15, 2024

Price target increased by 14% to US$84.55

Bruker Corporation Provides Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Bruker Corporation (NasdaqGS:BRKR) acquired Nanophoton Corporation.

Bruker Corporation to Report Q4, 2023 Results on Feb 13, 2024

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire Chemspeed Technologies AG.

Calculating The Fair Value Of Bruker Corporation (NASDAQ:BRKR)

There's Reason For Concern Over Bruker Corporation's (NASDAQ:BRKR) Price

Bruker Corporation (NasdaqGS:BRKR) acquired Tornado Spectral Systems.

Should You Be Adding Bruker (NASDAQ:BRKR) To Your Watchlist Today?

Bruker Corporation Announces Quarterly Dividend, Payable on December 15, 2023

Is Bruker Corporation (NASDAQ:BRKR) Potentially Undervalued?

Price target decreased by 11% to US$70.56

Bruker Corporation Revises Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chairman exercised options to buy US$3.4m worth of stock.

Bruker Corporation to Report Q3, 2023 Results on Nov 02, 2023

Now 21% undervalued after recent price drop

Is Bruker (NASDAQ:BRKR) Using Too Much Debt?

Price target decreased by 8.7% to US$80.89

Bruker Corporation Introduces Next-Generation Nanomechanical Test System

Insufficient new directors

Here's Why Bruker (NASDAQ:BRKR) Has Caught The Eye Of Investors

Bruker Introduces Novel 4D-Proteomics™ Timstof® Capabilities

Bruker Corporation Provides Revenue Guidance for Fiscal Year 2023

Upcoming dividend of US$0.05 per share at 0.3% yield

Bruker Corporation (NasdaqGS:BRKR) signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc. (NasdaqGS:CELL).

Bruker Corporation Approves Payment of Quarterly Cash Dividend in on the Company’s Common Stock, Payable on September 15, 2023

Chairman notifies of intention to sell stock

Does This Valuation Of Bruker Corporation (NASDAQ:BRKR) Imply Investors Are Overpaying?

Bruker Corporation Raises Financial Outlook for Fiscal Year 2023